SEGMENT INFORMATION (Tables)

6 Months Ended

Apr. 30, 2023

Segment Reporting [Abstract]

SCHEDULE OF SEGMENT INFORMATION

	For the Three Months Ended April 30,						For the Six Months Ended April 30,
	2023			2022			2023			2022
Net income/(loss):
CAR-T Therapeutics	$	(997	)	$	(1,399	)	$	(1,908	)	$	(3,010	)
Cancer Vaccines		(913	)		(1,423	)		(1,871	)		(2,780	)
Anti-Viral Therapeutics		(416	)		(757	)		(898	)		(1,661	)
Other		19			(9	)		16			(16	)
Total	$	(2,307	)	$	(3,588	)	$	(4,661	)	$	(7,467	)
Total operating costs and expenses	$	2,770		$	3,589		$	5,326		$	7,469
Less non-cash stock-based compensation		(1,227	)		(1,745	)		(2,290	)		(4,099	)
Operating costs and expenses excluding non-cash stock-based compensation	$	1,543		$	1,844		$	3,036		$	3,370
Operating costs and expenses excluding non-cash stock-based compensation:
CAR-T Therapeutics	$	620		$	733		$	1,218		$	1,402
Cancer Vaccines		523			716			1,111			1,196
Anti-Viral Therapeutics		212			388			517			760
Other		188			7			190			12
Total	$	1,543		$	1,844		$	3,036		$	3,370

	April 30, 2023		October 31, 2022
Total assets:
CAR-T Therapeutics	$	11,682	$	16,921
Cancer Vaccines		10,638		9,442
Anti-Viral Therapeutics		4,953		3,811
Other		326		238
Total	$	27,599	$	30,412